Company logo

PLRX - Pliant Therapeutics, Inc.

NASDAQ -> Healthcare -> Biotechnology
South San Francisco, United States
Type: Equity

PLRX price evolution
PLRX
(in millions $) 30 Sep 2022 30 Jun 2022 31 Mar 2022 31 Dec 2021
Current assets
Cash $44.62 $25.07 $32.55 $51.66
Short term investments $315.62 $138.53 $145.74 $148.93
Net receivables $1.48 $4.99 $1.25 $2
Inventory
Total current assets $365.96 $173.53 $185.36 $209.44
Long term investments
Property, plant & equipment $10.82 $10.18 $10.82 $10.94
Goodwill & intangible assets
Total noncurrent assets $11.22 $11.09 $11.66 $11.77
Total investments $315.62 $138.53 $145.74 $148.93
Total assets $377.18 $184.62 $197.02 $221.22
Current liabilities
Accounts payable $3.21 $3.12 $4.68 $2.97
Deferred revenue
Short long term debt $2.65 $2.04 $2 $1.87
Total current liabilities $26.16 $22.55 $18.31 $16.83
Long term debt $14.03 $14.28 $4.92 $5.33
Total noncurrent liabilities $14.03 $14.28 $4.92 $5.33
Total debt $16.68 $16.32 $6.92 $7.19
Total liabilities $40.19 $36.83 $23.23 $22.16
Shareholders' equity
Retained earnings -$303.35 -$272.74 -$243.19 -$215.09
Other shareholder equity -$2.45 -$1.26 -$0.95 -$0.2
Total shareholder equity $336.99 $147.79 $173.79 $199.06
(in millions $) 31 Dec 2021 31 Dec 2020 31 Dec 2019 31 Jan 2019
Current assets
Cash $51.66 $50.88 $85.81 $60.95
Short term investments $148.93 $226.01 $16.97
Net receivables $2 $9.28 $7.05 $0.5
Inventory
Total current assets $209.44 $290.75 $111.9 $61.73
Long term investments
Property, plant & equipment $10.94 $4.32 $4.08 $4.26
Goodwill & intangible assets
Total noncurrent assets $11.77 $4.77 $7.16 $4.8
Total investments $148.93 $226.01 $16.97
Total assets $221.22 $295.53 $119.06 $66.53
Current liabilities
Accounts payable $2.97 $2.02 $1.25 $2.58
Deferred revenue
Short long term debt $1.87
Total current liabilities $16.83 $11.6 $8.17 $5.08
Long term debt $5.33
Total noncurrent liabilities $5.33 $0.87 $0.91 $0.81
Total debt $7.19
Total liabilities $22.16 $12.46 $9.08 $5.89
Shareholders' equity
Retained earnings -$215.09 -$117.83 -$76.3 -$71.47
Other shareholder equity -$0.2 -$0.03 -$0 $132.1
Total shareholder equity $199.06 $283.06 -$76.3
(in millions $) 30 Sep 2022 30 Jun 2022 31 Mar 2022 31 Dec 2021
Revenue
Total revenue $1.48 $4.99 $1.25 $2
Cost of revenue
Gross Profit $1.48 $4.99 $1.25 $2
Operating activities
Research & development $24.61 $26.34 $20.88 $18.75
Selling, general & administrative $8.82 $8.3 $8.58 $7.85
Total operating expenses $33.43 $34.63 $29.46 $26.6
Operating income -$31.95 -$29.64 -$28.21 -$24.6
Income from continuing operations
EBIT -$30.61 -$29.55 -$28.1 -$24.53
Income tax expense
Interest expense
Net income
Net income -$30.61 -$29.55 -$28.1 -$24.53
Income (for common shares) -$30.61 -$29.55 -$28.1 -$24.53
(in millions $) 31 Dec 2021 31 Dec 2020 31 Dec 2019 31 Jan 2019
Revenue
Total revenue $7.57 $41.82 $57.05
Cost of revenue
Gross Profit $7.57 $41.82 $57.05
Operating activities
Research & development $77.55 $66.19 $47.35
Selling, general & administrative $27.56 $17.27 $10.93
Total operating expenses $105.11 $83.46 $58.28 $30.91
Operating income -$97.53 -$41.65 -$1.23 -$30.91
Income from continuing operations
EBIT -$97.26 -$41.53 -$0.63
Income tax expense
Interest expense
Net income
Net income -$97.26 -$41.53 -$0.63 -$30.28
Income (for common shares) -$97.26 -$41.53 -$6.86
(in millions $) 30 Sep 2022 30 Jun 2022 31 Mar 2022 31 Dec 2021
Net income -$30.61 -$29.55 -$28.1 -$24.53
Operating activities
Depreciation $1.03 $0.9 $0.7 $2.09
Business acquisitions & disposals
Stock-based compensation $4.81 $3.4 $3.53 $2.77
Total cash flows from operations -$18.5 -$24.4 -$20.5 -$19.86
Investing activities
Capital expenditures -$0.7 -$0.25 -$0.64 -$0.59
Investments -$177.56 $6.75 $2.17 $26.38
Total cash flows from investing -$178.25 $6.5 $1.53 $25.78
Financing activities
Dividends paid
Sale and purchase of stock $217.01 $0.45 $0.05 $0.54
Net borrowings $9.85
Total cash flows from financing $216.3 $10.43 -$0.15 $0.52
Effect of exchange rate
Change in cash and equivalents $19.55 -$7.47 -$19.12 $6.43
(in millions $) 31 Dec 2021 31 Dec 2020 31 Dec 2019 31 Jan 2019
Net income -$97.26 -$41.53 -$0.63 -$30.28
Operating activities
Depreciation $3.2 $1.31 $1.11
Business acquisitions & disposals
Stock-based compensation $10.44 $3.9 $1.83
Total cash flows from operations -$75.44 -$37.27 -$2.75 -$28.33
Investing activities
Capital expenditures -$1.95 -$1.53 -$0.96
Investments $75.65 -$209.33 -$16.71
Total cash flows from investing $73.7 -$210.87 -$17.93 -$2.32
Financing activities
Dividends paid
Sale and purchase of stock $2.98 $161.19 $0.17
Net borrowings
Total cash flows from financing $2.53 $213.21 $45.54 $87.35
Effect of exchange rate
Change in cash and equivalents $0.78 -$34.92 $24.86 $56.7
Fundamentals
Market cap $1.59B
Enterprise value $1.56B
Shares outstanding 48.75M
Revenue $9.72M
EBITDA -$108.08M
EBIT -$112.79M
Net Income -$112.79M
Revenue Q/Q -7.95%
Revenue Y/Y -3.18%
P/E ratio -14.09
EV/Sales 160.69
EV/EBITDA -14.45
EV/EBIT -13.85
P/S ratio 163.57
P/B ratio 4.68
Book/Share 6.96
Cash/Share 0.92
EPS -$2.31
ROA -46.04%
ROE -52.61%
Debt/Equity 0.11
Net debt/EBITDA 0.04
Current ratio 13.99
Quick ratio 13.99